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I. OBJECTIVE EVIDENCE OF NONOBVIOUSNESS IN AIA
POST-GRANT PROCEEDINGS
Obviousness may be raised by a Petitioner as a ground of
unpatentability in both inter partes review (IPR) and post-grant
review (PGR) proceedings.6  The Patent Trial and Appeal Board
(PTAB) may institute an IPR or PGR if "there is a reasonable
likelihood that the petitioner would prevail with respect to at least 1
of the claims challenged in the petition" (IPR) or "it is more likely
than not that at least 1 of the claims challenged in the petition is
unpatentable" (PGR).7 In making a decision to institute an IPR,
PTAB may consider a Patent Owner's Preliminary Response (POPR),
if one was filed, arguing why the proceeding should not be instituted.8
For a PGR, the statutory language for the institution threshold is a
little different (if the information in the petition is "not rebutted"), 9
but it is reasonable to expect that the only way the information could
be rebutted is in a Patent Owner's Preliminary Response. 10 The
6 35 U.S.C. § 311(b) (2013); 35 U.S.C. §321(b) (2012).
7 35 U.S.C. § 314(a) (2012) ("Institution of inter partes review (a)
THRESHOLD.-The Director may not authorize an inter partes review to be
instituted unless the Director determines that the information presented in the
petition filed under section 311 and any response filed under section 313 shows that
there is a reasonable likelihood that the petitioner would prevail with respect to at
least 1 of the claims challenged in the petition.").
35 U.S.C. § 324(a) (2012) ("Institution of post-grant review (a) THRESHOLD.-The
Director may not authorize a post-grant review to be instituted unless the Director
determines that the information presented in the petition filed under section 321, if
such information is not rebutted, would demonstrate that it is more likely than not
that at least 1 of the claims challenged in the petition is unpatentable.").
8 35 U.S.C. § 314(a) (2012).
9 35 U.S.C. § 324(a) (2012). See also, Office Patent Trial Practice Guide, 77 Fed.
Reg. 48,756, 48,763 (Aug. 14, 2012) ("The Board expects that most petitions will raise
issues of obviousness. In determining whether the subject matter of a claim would
have been obvious over the prior art, the Board will review any objective evidence of
nonobviousness proffered by the patent owner where appropriate.").
10 In addition, the Office Patent Trial Practice Guide treats POPRs in IPRs and
PGRs the same. See Office Patent Trial Practice Guide, 77 Fed. Reg. 48,756, 48,764
(Aug. 14, 2012) ("The preliminary response may present evidence other than new
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POPR is the only filing available to the Patent Owner prior to
PTAB's decision to institute.
Objective evidence of nonobviousness may be raised by the
Patent Owner in its POPR to convince PTAB that the petition should
be denied, although the Patent Owner currently cannot generate new
declarations or factual evidence for use in the POPR.11 On Aug. 20,
2015, the United States Patent & Trademark Office (USPTO)
released proposed rules that may change the use of new evidence in
POPRs. The proposed rule showing the proposed amendment in
italics reads:
§ 42.107 Preliminary response to petition.
(a) The patent owner may file a preliminary response to
the petition. The response may set forth the reasons why
no inter partes review should be instituted under 35 U.S.C.
314 and can include supporting evidence. The preliminary
response is subject to the word count under § 42.24.12
After institution, objective evidence of nonobviousness may be
raised in the Patent Owner's Response (POR),'13 this time with newly-
generated declarations and additional factual evidence.
In IPRs so far, Patent Owners have experienced significant
disappointment before PTAB with arguments based on objective
evidence of nonobviousness. This article will examine the types of
objective evidence that may be raised and examples of objective
testimonial evidence to demonstrate that no review should be instituted. §§ 42.107(c)
and 42.207(c).").10 37 C.F.R. § 42.107(c) (2012); 37 C.F.R. § 42.207(c) (2012).
11 Id.
12 Same proposed change for 37 C.F.R. § 42.207 relating to POPRs in PGRs.
Also, there is a proposed change to 37 C.F.R. § 42.108 to provide an opportunity for
the Petitioner to respond to new testimony generated for the POPR prior to the
institution decision:
37 C.F.R. § 42.108 Institution of interpartes review.
(c) Sufficient grounds. Inter partes review shall not be instituted for a ground of
unpatentability unless the Board decides that the petition supporting the ground
would demonstrate that there is a reasonable likelihood that at least one of the claims
challenged in the petition is unpatentable. The Board's decision will take into account
a patent owner preliminary response where such a response is filed, but supporting
evidence concerning disputed material facts will be viewed in the light most favorable
to the petitioner for purposes of deciding whether to institute an inter partes review.
If the patent owner submits supporting evidence with its preliminary response, the
petitioner may seek leave to file a reply to the preliminary response in accordance
with § 42.24(c).
13 35 U.S.C. § 316(a)(8) (2012); 35 U.S.C. § 326(a)(8) (2012).
2015]
108 BUFFALO INTELLECTUAL PROPERTY LAW JOURNAL [Vol XI
evidence arguments in IPRs. We will also discuss why Patent Owners
have experienced failure relying on objective evidence of
nonobviousness, as well as suggest possible courses of action to obtain
better results.
A. Same Types of Objective Evidence Can Be Raised in USPTO
Proceeding or District Court Litigation or International Trade
Commission Litigation
The types of objective evidence in any proceeding, whether
judicial or administrative, are the same. Objective evidence of
nonobviousness has been an integral part of a court's obviousness
inquiry since at least Graham v. John Deere, 383 U.S. 1, 17-18 (U.S.
1966). 14  The Manual of Patent Examining Procedure (MPEP)
expressly relies on Graham v. John Deere in its Examination
Guidelines for Determining Obviousness Under 35 U.S.C. § 103."5
MPEP § 2145 outlines examples of objective evidence: commercial
success, long-felt but unsolved needs, failure of others, industry
praise/skepticism, unexpected properties, unexpected results, and
copying.
B. Objective, Real World Evidence May Be Strongest Possible
Evidence of Nonobviousness
The Federal Circuit has acknowledged that objective evidence of
nonobviousness may be the strongest evidence of nonobviousness. 16
The MPEP instructs that examiners "should consider all rebuttal
arguments and evidence presented by applicants [which] may include
evidence of 'secondary considerations,' such as 'commercial success,
long felt but unsolved needs, [and] failure of others.' Graham v. John
Deere Co., 383 U.S. 1, 148 USPO 4459, 467." 17 In fact, if present, such
objective evidence must be considered fully and not merely for its
14 Graham v. John Deere, 383 U.S. 1, 17-18 (U.S. 1966) ("Under s 103, the scope
and content of the prior art are to be determined; differences between the prior art
and the claims at issue are to be ascertained; and the level of ordinary skill in the
pertinent art resolved. Against this background, the obviousness or nonobviousness
of the subject matter is determined. Such secondary considerations as commercial
success, long felt but unsolved needs, failure of others, etc., might be utilized to give
light to the circumstances surrounding the origin of the subject matter sought to be
patented. As indicia of obviousness or nonobviousness, these inquiries may have
relevancy.").
15 Manual of Patent Examining Procedure §2141 (2014).
16 See Crocs, Inc. v. Int'l Trade Comm'n, 598 F.3d 1294, 1310 (Fed. Cir. 2010)
(noting objective indicia "can be the most probative evidence of nonobviousness in
the record, and enable[] the ... court to avert the trap of hindsight.").
17 Manual of Patent Examining Procedure § 2145 (2014).
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"knockdown" value, and the examiner must reweigh all evidence to
determine whether the claims are nonobvious.18
C. When Can Objective Evidence Be Raised?
Objective evidence of nonobviousness may be submitted by the
Patent Owner in the POPR if such evidence already exists, such as in
the file history of the challenged patent or otherwise not "taken
specifically for the purpose of the inter partes review." 19 Objective
evidence of nonobviousness may also be submitted with the POR,
whether or not the objective evidence is newly-generated.2 °
1. Examples of Petitioner Pre-Emptively Raising in Petition to
Try to Cut Off at the Pass the Effect of Any Such Evidence That
Might Later Be Raised by the Patent Owner
a. Conopco, Inc. v. Procter & Gamble Co.,
No. IPR2013-00505, -00510
In Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00505,
Petitioner raised objective evidence of nonobviousness in the Petition.
After detailing all of its unpatentability arguments, the Petition closed
on a section entitled "Objective Indicia of Nonobviousness," and
proceeded to challenge Patent Owner's possible objective evidence of
nonobviousness, in this case, unexpected results. Petitioner argued
that any assertions of unexpected results must fail because the prior
art discloses those same results; "[u]nexpected results must be
"different in kind and not merely in degree from the results of the
prior art." citing In re Aller, 220 F.2d 454, 456 (C.C.P.A. 1955).21
Patent Owner responded in the POPR by indicating that it would
submit objective evidence of nonobviousness in the form of
18 See id. (noting "Evidence pertaining to secondary considerations must be
taken into account whenever present; however, it does not necessarily control the
obviousness conclusion .... Office personnel should not evaluate rebuttal evidence
for its 'knockdown' value against the prima facie case .... Rather, all evidence must
be reweighed to determine whether the claims are nonobvious.").
19 See 37 C.F.R. §§ 42.107 (2012); see also, Anova Food, LLC v. Sandau, No.
IPR2013-00114, Paper 11, at 3 (P.T.A.B. June 25, 2013) (noting "The Board
responded that 37 C.F. R § 42.107(c) applies only to "new" testimony that was taken
specifically for the purpose of the inter partes review proceeding at issue, as
supported by the discussion and the comments that accompanied the rule. For
example, a party submitting the prosecution history for the challenged patent may
include a copy of the declarations contained therein.").
20 35 U.S.C. §316(a)(8) (2012) and 35 U.S.C. §326(a)(8) (2012).
21 Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00505, Paper 4 (P.T.A.B.
Aug. 13, 2013).
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unexpected results and commercial success if PTAB instituted an IPR
on any obviousness ground of the Petition.22 Patent Owner also
quoted the Examiner's Reasons for Allowance: "[t]he instant
invention demonstrates an improvement over prior art formulations
due to the surprising and beneficial results that are attained through
these index criteria.
23
PTAB instituted trial on some of the challenged claims, but not
all. It did not address the objective evidence issue in its institution
24decision.
Patent Owner proceeded to raise objective evidence in its POR,
but it was not evidence of unexpected results as Petitioner had
anticipated.25 Instead, Patent Owner argued commercial success and
long-felt but unmet need, supported by expert declarations prepared
for the IPR, tipped the balance in favor of nonobviousness.26 PTAB
was not persuaded and held the instituted claims unpatentable. 27 In
particular, PTAB found the expert declarations lacking in persuasive
value and that Patent Owner failed to show sufficient nexus between
the objective evidence and the claimed invention.28
The same petitioner used the pre-emptive tactic again in the
IPR2013-00510 Petition: "P&G may attempt to avoid a finding of
obviousness by asserting that the shampoo compositions claimed in
the '155 patent achieve unexpected results or by arguing the criticality
of the recited ranges for the components of the shampoo
compositions.",29 Patent Owner again responded in the POPR by
indicating that it would submit objective evidence of nonobviousness
in the form of unexpected results and commercial success if PTAB
instituted an IPR on any obviousness ground of the Petition.30 PTAB
denied institution on all challenged claims, but did not address the
22 Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00505, Paper 8, at 50-51
(P.T.A.B. Nov. 15, 2013).
23 Id. at 37.
24 Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00505, Paper 9 (P.T.A.B.
Feb. 12, 2014).
25 Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00505, Paper 34
(P.T.A.B. July 25, 2014).
26 Id. at 57-60.
27 Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00505, Paper 69
(P.T.A.B. Feb. 10, 2015).
28 Id. at 25-28.
29 Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00510, Paper 2, at 59
(P.T.A.B. Aug. 14, 2013).
30 Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00510, Paper 7, at 45-46
(P.T.A.B. Nov. 18, 2013).
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31
objective evidence issue.
b. Actavis, Inc. v. Research Corporation Technologies, Inc.,
No. IPR2014-01126
Another petitioner employed a preemptive strike in Actavis, Inc.
v. Research Corporation Technologies, Inc., No. IPR2014-01126,
closing the petition by stating that although the Patent Owner may try
to argue unexpected properties, long-felt but unmet need, and
copying, it would "preliminarily address these alleged secondary
considerations[.] 3 2 According to Petitioner, the claimed compound
did not have unexpected properties ("the R stereoisomer's superior
potency was not only expected-it was known"3 3), there was no
evidence of a long-felt but unmet need for an effective method of
treating patients suffering from partial-onset seizures ("there were
'many' 'well known anticonvulsants' . . . "useful in the control of
generalized seizures and all forms of partial seizures.'"3 4), the fact that
no one else had made and commercialized the claimed compound "is
irrelevant," and copying by generic producers is an FDA requirement,
not proof of nonobviousness.35
Patent Owner included arguments in its POPR as to why
Petitioner's assertions were incorrect, and noted that if an IPR was
instituted on the obviousness ground asserted, it would present
objective evidence of nonobviousness in its POR.3 6 It argued that the
properties of the racemate were not known and Petitioner failed to
consider the absence of chronic toxicity. 37 Furthermore, there was a
long-felt but "unmet need for antiepileptic treatments that were both
effective and safe over both the short term and the long term. 38 At
the time of the invention, no one else thought that lacosamide was
worth investigating.39
PTAB denied institution because the Petitioner's reference on
31 Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00510, Paper 9 (P.T.A.B.
Feb. 12, 2014).
32 Actavis, Inc. v. Research Corporation Technologies, Inc., No. IPR2014-01126,
Paper 6, at 50 (P.T.A.B. July 10, 2014).
3Id.
34 Id. at 52.
31 Id. at 52-53.
36 Actavis, Inc. v. Research Corporation Technologies, Inc., No. IPR2014-01126,
PaPer 19, at 56-57 (P.T.A.B. Oct. 23, 2014).
7 Id. at 57.
38 Id. at 58.
31 Id. at 59.
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which its unpatentability grounds were based was not prior art.40 The
objective evidence issue was not discussed.41
c. Pharmatech Solutions, Inc. v. Lifescan Scotland, Ltd.,
No. IPR2013-00247
Petitioner in Pharmatech Solutions, Inc. v. Lifescan Scotland,
Ltd., No. IPR2013-00247, somewhat cursorily, stated that:
the patent owner may attempt to argue secondary
considerations of nonobviousness, such as commercial
success. However, there is no nexus between the patent
claims and the success of the product marketed under the
'105 Patent. So secondary considerations do not support
patentability, and clearly do not overcome the strong
showing of obviousness made herein.42
Patent Owner answered the assertion in its POPR, noting that
Petitioner was ignoring that the district court in the related litigation
found the objective evidence supported nonobviousness.43 Patent
Owner provided the district court evidence of commercial success and
copying as exhibits to its POPR.44
PTAB instituted trial on all challenged claims on two of the 13
asserted grounds. It did not discuss the objective evidence of
nonobviousness.45
d. St. Jude Med. v. Board of Regents of Univ. of Michigan,
No. IPR2013-00041
In St. Jude Med. v. Board of Regents of Univ. of Michigan, No,
IPR2013-00041, Petitioner argued in the Petition that, based on the
40 Actavis, Inc. v. Research Corporation Technologies, Inc., No. IPR2014-01126,
PaPer 21 (P.T.A.B. Jan. 9, 2015).
T Id.
42 Pharmatech Solutions, Inc. v. Lifescan Scotland, Ltd., No. IPR2013-00247,
Paper 1, at 10 (P.T.A.B. April 11, 2013).
43 Pharmatech Solutions, Inc. v. Lifescan Scotland, Ltd., No. IPR2013-00247,
Paper 10, at 1-2 (P.T.A.B. July 17, 2013).
44 Pharmatech Solutions, Inc. v. Lifescan Scotland, Ltd., No. IPR2013-00247,
Paper 10 (P.T.A.B. July 17, 2013); see also Amneal PharmaceuticalS, LLC v.
Supernus Pharmaceuticals, LLC, No. IPR2013-00368, Paper 6 (P.T.A.B. Sept. 23,
2013) (where Patent Owner submitted district court records as exhibits attached to
the POPR).
45 Pharmatech Solutions, Inc. v. Lifescan Scotland, Ltd., No. IPR2013-00247,
Paper 10 (P.T.A.B. July 17, 2013).
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prior art asserted as the grounds for unpatentability, Patent Owner
would not be able to show that any superior results were unexpected
or that there was any commercial success or long-felt but unmet need
tied to the merits of the claim invention.46
Patent Owner did not file a POPR, and trial was instituted on all
challenged claims based on 2 of the 7 asserted grounds. 47 No mention
was made in the POPR of the suggested objective evidence the Patent
Owner might raise.
After institution, Patent Owner filed a response that is
confidential under a protective order. The Petitioner's Reply,
however, indicates that Patent Owner argued commercial success and
long-felt but unmet need.48
PTAB found all instituted claims unpatentable.49  PTAB
discussed the objective evidence of nonobviousness, but found it
unpersuasive. In particular, PTAB found that Michigan failed to
sufficiently establish "that the St. Jude products enjoyed commercial
success, or a nexus between any success and the invention
claimed[.] ' '50  In addition, arguments for long-felt but unmet need
were undermined by a showing on the record that the need, if present,
was met prior to the claimed invention.5t
e. Scotts Company LLC v. Encap, LLC, No. IPR2013-00491
Scotts preemptively argued that Encap's prosecution evidence of
long-felt need and copying was insufficient because at best the claims
were broader than the product Encap asserted was copied and filled
the long-felt need. According to Scotts, the "Examiner did not rely on




46 St. Jude Med. v. Board of Regents of Univ. of Michigan, No. 1PR2013-00041,
Paper 1, at 58-59 (P.T.A.B. Nov. 9, 2012).
St. Jude Med. v. Board of Regents of Univ. of Michigan, No. IPR2013-00041,
Paper 12 (P.T.A.B. May 2, 2013). There is a POPR is listed after the Final Written
Decision and indicated as entered on June 16, 2015, signed and served on Aug. 2,
2013; conversely, the institution decision clearly states, "[tihe Patent Owner, The
Board of Regents of the University of Michigan ('University of Michigan'), did not
file a preliminary response opposing institution of review." Id. at 2; St. Jude Med. v.
Board of Regents of Univ. of Michigan, No. IPR2013-00041, Paper 1072, at 48
(P.T.A.B. June 16, 2014).
48 St. Jude Med. v. Board of Regents of Univ. of Michigan, No. IPR2013-00041,
Paper 29, at 11-14 (P.T.A.B. Nov. 1, 2013).
St. Jude Med. v. Board of Regents of Univ. of Michigan, No. IPR2013-00041,
Paper 69 (P.T.A.B. May 1, 2014).
50 Id. at 25.
51 Id. at 28.
52 Scotts Company LLC v. Encap, LLC, No. IPR2013-00491, Paper 1, at 18 n. 8
(P.T.A.B. Aug. 2, 2013).
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In response, Encap included objective evidence of
nonobviousness in its POPR as additional reasons why inter partes
review should be denied.53 First, Encap noted that the Notice of
Allowance said nothing about whether or not the Examiner relied on
the secondary consideration arguments.54 In addition, marketing
literature, a Scotts video, and Scotts' failure to independently develop
a product with a color indicator were all evidence of a long-felt but
unmet need in the industry for a product that addressed the need to
know when and how long to water.55
According to Encap, Scotts copied Encap after Encap
confidentially disclosed the color indicator technology in June 2002.
Scotts was then successful at convincing the market that it was the
innovator of this technology.56
PTAB denied institution on all challenged claims without
addressing the objective evidence of nonobviousness.57
f. Mylan Pharms. Inc. v. Gilead Sciences, Inc.,
No. IPR2014-00888
Mylan's Petition addressed objective evidence of nonobviousness
raised by Gilead in the reexamination of the patent claims at issue.58
According to Mylan, Gilead's evidence of surprising and unexpected
results, long-felt need, and commercial success did not outweigh the
evidence of obviousness. 59 The prior art showed that the allegedly
surprising results were known, and there was no nexus between the
commercial success or long-felt need and the claimed compound (as
opposed to the claimed compound in combination therapies).6 °
Gilead countered in its POPR by both arguing that the examiner
correctly evaluated the objective evidence of nonobviousness in the
53 Scotts Company LLC v. Encap, LLC, No. IPR2013-00491, Paper 8, at 40-47
(P.T.A.B. Nov. 8, 2013).
54 Id. at 40.
55 Id. at 40-47.
56 Id. at 44-47.
57 Scotts Company LLC v. Encap, LLC, No. IPR2013-00491, Paper 9 (P.T.A.B.
Feb. 5, 2014).
58 A reexamination certificate was issued in 2008. See also Mylan Pharms. Inc. v.
Gilead Sciences, Inc., No. IPR2014-00888, Paper 1, at 4 (P.T.A.B. Jun. 3, 2014); see
also, Mylan Pharms. Inc. v. Gilead Sciences, Inc., No. IPR2014-00885 (P.T.A.B. Dec.
9, 2014); Mylan Pharms. Inc. v. Gilead Sciences, Inc., No. IPR2014-00886 (P.T.A.B.
Dec. 17, 2014); Mylan Pharms. Inc. v. Gilead Sciences, Inc., No. IPR2014-00887
(P.T.A.B. Dec. 9, 2014).
59 Mylan Pharms. Inc. v. Gilead Sciences, Inc., No. IPR2014-00888, Paper 4, at 49
(P.T.A.B. June 24, 2014).
60 Id. at 49-52.
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reexamination and the details supporting why the objective evidence
of nonobviousness was persuasive. 61 For example, the commercial
success evidence of sales figures related to a drug in which the claimed
compound was the sole active ingredient.62
PTAB denied institution on all challenged claims without
addressing the objective evidence of nonobviousness.
63
g. Coalition For Affordable Drugs (ADROCA) LLC v.
Acorda Therapeutics, Inc., No. IPR2015-00720
The petitioner in Coalition For Affordable Drugs (ADROCA)
LLC v. Acorda Therapeutics, Inc., No. IPR2015-00720, concluded its
obviousness assertions in its Petition with a section noting that the
Patent Owner did not submit any objective evidence of
nonobviousness during prosecution.64  Moreover, the objective
evidence of nonobviousness submitted during prosecution of the
parent application was insufficient in relation to the claims at issue
because that evidence was not connected to the claim limitation at
issue: "at least [a] two week period., 65 A declaration supporting
unexpected results was filed in the parent application, but there is
nothing in the prosecution history indicating that the examiner relied
on the declaration as a factor for issuing the parent claims.
66
Acorda filed a POPR, arguing that Petitioner bore the burden of
showing invalidity and failed to counter Patent Owner's evidence of
commercial success, long-felt but unsolved needs, and failure of
others, that was also submitted during the prosecution. Patent Owner
attached as exhibits several declarations submitted during prosecution
addressing objective evidence. 67
PTAB denied institution on all challenged claims without
addressing the issue of objective evidence of nonobviousness.68
61 Mylan Pharms. Inc. v. Gilead Sciences, Inc., No. IPR2014-00888, Paper 8, at 52-
56 (P.T.A.B. Sept. 18, 2014).
2 Id. at 54-55.
63 Mylan Pharms. Inc. v. Gilead Sciences, Inc., No. IPR2014-00888, Paper 15
(P.T.A.B. Dec. 9, 2014).
64 Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics,
Inc., No. IPR2015-00720, Paper 7, at 53 (P.T.A.B. March 5, 2015).
65 Id. at 54.
I d. at 55.
67 Coalition For Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics,
Inc., No. IPR2015-00720, Paper 10 (P.T.A.B. May 26, 2015).
68 Coalition For Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics,
Inc., No. IPR2015-00720, Paper 15 (P.T.A.B. Aug. 24, 2015).
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2. Examples of Patent Owner Raising Objective Evidence in
Patent Owner Preliminary Response
a. Medtronic, Inc. v. Nuvasive, Inc., No. IPR2014-00073
In its POPR, NuVasive argued, inter alia, that Medtronic's
petition should be denied because it "failed to consider or even
address objective indicia of nonobviousness." 69 Objective evidence
which, according to NuVasive, Medtronic knew about, included
commercial success, initial disbelief by experts, eventual praise by
competitors, and copying by those same competitors. As evidence of
Medtronic's knowledge, NuVasive submitted a Medtronic
presentation showing "a chart of NuVasive's skyrocketing sales.",70
NuVasive argued that the Medtronic itself expressed initial skepticism
and eventual praise and copying.7'
PTAB instituted a trial on 7 of the 9 challenged claims.72 In doing
so, it noted that it was not persuaded by the objective evidence
presented by Patent Owner because there was no "clear or specific
evidence explaining what ... features, if any, of the challenged claims,
are part of the XLIF system. It is, therefore, not clear, on the current
record, that any of the alleged secondary indicia of non-obviousness
relate to the surgical system recited in the challenged claims., 73
In the POR, the Patent Owner used 27 pages to discuss objective
evidence of nonobviousness, including long-felt but unmet need,
initial skepticism, praise and recognition by industry, superior results,
commercial success, and copying.74  Patent Owner submitted
supporting expert declarations. Patent Owner also alleged that
Petitioner knew of this evidence (again, based on Petitioner's internal
documents), and that Petitioner withheld such evidence from its
expert.75
In its Reply, Petitioner argued that Patent Owner's evidence was
faulty because it did not relate to claimed features but rather several
69 Medtronic, Inc. v. Nuvasive, Inc., No. IPR2014-00073, Paper 10, at 31 (P.T.A.B.
Jan. 31, 2014).
70 Id. at 32.
71 Id. at 49-50.
72 Medtronic, Inc. v. Nuvasive, Inc., No. IPR2014-00073, Paper 14 (P.T.A.B. April
8, 2014).
73 Id. at 19.
74 Medtronic, Inc. v. Nuvasive, Inc., No. IPR2014-00073, Paper 26 (P.T.A.B. July
8, 2014). This is one of the few cases where the Patent Owner argued objective
evidence of nonobviousness before substantively countering the obviousness positions
of the Petitioner.
75 Id. at 2 and 34.
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unclaimed features.76
PTAB issued a final written decision holding the instituted
claims unpatentable.77 PTAB rejected the objective evidence of
nonobviousness for insufficient nexus to the claimed invention:
In the instant case, Petitioner persuades us that the
evidence of secondary considerations is not entitled to
substantial weight, because Patent Owner has not
established a sufficient nexus between the claimed
subject matter and that evidence. Petitioner persuades
us also that the evidence of secondary considerations is
not reasonably commensurate in scope with the
claimed subject matter.78
b. Phigenix, Inc. v. Genentech, Inc., No. IPR2014-
00842
According to Patent Owner Genentech, Phigenix's Petition
should fail because, among other things, it (and the supporting expert
declaration) failed to "challenge the merits of Patent Owner's
secondary consideration evidence" raised during prosecution. 79 The
prosecution history included data submitted to the examiner showing
that the claimed methods for administering a trastuzumab-
maytansinoid conjugate yielded unexpected results. In a related
application, there was additional further evidence of unexpected
results. The Patent Owner provided a detailed discussion of the
unexpected results and submitted the prosecution declaration as a
supporting exhibit.
80
Patent Owner also argued that Phigenix failed to address praise
by others, including by Petitioner's expert prior to his retention for
this case.81
PTAB denied the Petition with respect to all challenged claims,
76 Medtronic, Inc. v. Nuvasive, Inc., No. IPR2014-00073, Paper 31, at 4 (P.T.A.B.
Oct. 3, 2014), citing Institut Pasteur v. Focarino, 738 F.3d 1337, 1346-47 (Fed. Cir.
2013).
7 Medtronic, Inc. v. Nuvasive, Inc., No. IPR2014-00073, Paper 48 (P.T.A.B. Apr.
3, 2015).
78 Medtronic, Inc. v. Nuvasive, Inc., No. IPR2014-00073, Paper 48, at 22 (P.T.A.B.
Apr. 3,2015).
79 Phigenix, Inc. v. Genentech, Inc., No. IPR2014-00842, Paper 9, at 17 (P.T.A.B.
Sept. 10, 2014).
80 Id. at 18-21.81 ld. at 21-22.
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but did not discuss the objective evidence of nonobviousness.82
3. Examples of Patent Owner Raising Objective Evidence in
Patent Owner Response
a. Conopco, Inc. v. Procter & Gamble Co.,
No. IPR2013-00505
The Patent Owner presented and argued objective evidence of
nonobviousness in its Patent Owner Response (POR), including
commercial success (evidence of sales of commercial embodiment of
invention) and long-felt but unmet need ("prior art anti-dandruff
conditioning shampoos existed but did not provide consumers with a
superior combination of anti-dandruff efficacy and conditioning
performance").83  In its Reply, Petitioner noted the absence of
unexpected results, and attacked Patent Owner's objective evidence
as conclusory, unsupported, and lacking a nexus with the claimed
invention.84
In the Final Written Decision, PTAB held that Patent Owner's
objective evidence of nonobviousness did not overcome the strong
showing of obviousness.85 PTAB appeared to find Patent Owner's
assertions insufficiently supported:
Patent Owner avers, without further elaboration, that
the Head & Shoulders® shampoo products "embody
the claims of the '569 patent" and, further, "is due to
the claimed features of the '569 patent." ...The
evidence upon which Patent Owner relies, but does not
discuss in any detail in its brief, consists of a single
sentence in the declaration of Dr. Lochhead: "Based
on my training and nearly 40 years of experience, it is
my opinion that the commercial success of [Patent
Owner's] Head & Shoulders® products that embody
82 Phigenix, Inc. v. Genentech, Inc., No. IPR2014-00842, Paper 10 (P.T.A.B. Dec.
9, 2014).
83 Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00505, Paper 34, at 57-60
(P.T.A.B. July 25, 2014).
84 Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00505, Paper 48, at 12-15
(P.T.A.B. Sept. 22, 2014).
85 Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00505, Paper 69, at 27-28(P.T.A.B. Feb. 10, 2015) ("[E]vidence of unexpected results and other secondary
considerations will not necessarily overcome a strong prima facie showing of
obviousness" quoting Sud-Chemie, Inc. v. Multisorb Techs., Inc., 554 F.3d 1001, 1009
(Fed. Cir. 2009)).
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the claims of the '569 patent is due to the claimed
features of the '569 patent, which represent the
consumer desired properties of the superior
combination of the anti-dandruff efficacy and
conditioning performance." We are not persuaded that
Dr. Lochhead's "training and nearly 40 years of
experience" relate sufficiently to shampoo
formulations; therefore, we find his testimony on that
point is entitled to little weight.86
According to PTAB, there was insufficient nexus shown between
the claimed invention and the alleged commercial success of the Head
& Shoulders@ shampoo products.8 7 Specifically, Patent Owner did
not "explain adequately how the Head & Shoulders@ products
allegedly embody the challenged claims; nor does Patent Owner
explain in any detail why it was the unique characteristics of the
claimed shampoo composition that drove sales.",8 8 There was similarly
an insufficient showing that the Head & Shoulders@ shampoo
products embody the claimed invention and that those products
satisfied a long-felt, but unmet need, among consumers.
8 9
PTAB also objected to Patent Owner presenting information
only in a declaration without sufficient discussion in the POR:
We will not play archeologist with the record to
discover evidentiary support for bare attorney
argument made in such a response. Id. We decline to
consider, moreover, information presented in a
supporting declaration, but not discussed sufficiently in
Patent Owner's Response. 90
b. Pharmatech Solutions, Inc. v. Lifescan Scotland, Ltd.,
No. IPR2013-00247
Patent Owner raised objective evidence of nonobviousness in its
POR, specifically evidence of copying by the Petitioner. 91 The district
86 Id. at 26.
87 Id.
88 Id. at 26-27.
89 Id. at 28.
90 Id. at 27. See also 37 C.F.R. § 42.6(a)(3): "Incorporation by reference;
combined documents. Arguments must not be incorporated by reference from one
document into another document. Combined motions, oppositions, replies, or other
combined documents are not permitted."
91 Pharmatech Solutions, Inc. v. Lifescan Scotland, Ltd., No. IPR2013-00247,
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court had found this to be "strong" evidence of nonobviousness.
92
Petitioner's Reply only commented that copying was necessary for its
product to work with Patent Owner's machine, and anyway, "evidence
of copying alone is insufficient.,
93
PTAB agreed with the Petitioner that the claims were
unpatentable for obviousness and the objective evidence was
insufficient because Patent Owner did not adequately show a "nexus"
between the copying and the claimed subject matter.94 "A nexus is
required in order to establish that the evidence relied upon traces its
basis to the claimed subject matter, not to another source." 95 In
particular, PTAB found that Pharmatech's copying was "motivated by
a desire to make Pharmatech's test strips compatible with LifeScan's
machine" 96 and Patent Owner did "not show or explain credibly how
this reason for copying relates to the claimed subject matter, as
opposed to unclaimed features, or to considerations unrelated to the
invention.
97
c. Permobil, Inc. v. Pride Mobility Products Corp.,
No. IPR2013-00407
Pride Mobility raised objective evidence of nonobviousness for
the first time in its POR by way of a declaration by the chairman of
the company describing competitor copying and commercial success.98
The evidence of copying was shown by a timeline comparing when the
Patent Owner's product, a 6-wheel wheelchair that had a low pivot
axis, was introduced against the introduction of a competitive product
by three other manufacturers starting about 2 years later.99 Evidence
of commercial success was shown through increase in sales and
market share after the commercialization of the claimed invention.100
The Patent Owner pointed out that the sales data were provided
broken down by particular models so that it was clear that the
Paper 16, at 46-48 (P.T.A.B. Nov. 15, 2013).
9 Id. at 48.
93 Pharmatech Solutions, Inc. v. Lifescan Scotland, Ltd., No. IPR2013-00247,
Paper 17, at 3-4 (P.T.A.B. Feb. 18, 2014).
94 Pharmatech Solutions, Inc. v. Lifescan Scotland, Ltd., No. IPR2013-00247,
Paper 27, at 22 (P.T.A.B. Aug. 6, 2014).95Id. at 20-21.
96 Id. at 21.
97 Id.
98 Permobil, Inc. v. Pride Mobility Products Corp., No. IPR2013-00407, Paper 23,
at 53-55 (P.T.A.B. March 20, 2014).
99 Id. at 54.
100 Id. at 56-57.
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patented invention was the reason for the commercial success. 1°1
Petitioner argued against Patent Owner's evidence of copying
because it did not show "actual efforts to replicate a specific
product.'0 2 It also considered the evidence of commercial success
insufficient because no nexus was shown: "none of the key factors
affecting market-share changes during the relevant time period
(pricing, promotion, and reimbursement) are related to the structural
feature of a wheelchair's front-arm pivot location.'
0 3
PTAB held all the challenged claims unpatentable. 10 4 In part, this
was because it agreed with Petitioner that Patent Owner did not
provide sufficient evidence of copying-particularly "evidence of
actual efforts to replicate a specific product.' ' 0 5  "None of the
evidence submitted by Patent Owner demonstrated that Invacare,
Sunrise Medical, or Petitioner was aware of the '598 patent prior to
developing its product[.]"' 06 PTAB also agreed that Patent Owner did
not establish sufficient nexus that the increased market share was
attributable to the claimed invention; evidence of increased sales did
not "establish sufficiently that customers were buying the Q600 and
Q6000 because of their low-pivot." 107
d. Captioncall, LLC v. Ultratec, Inc., No. 1PR2013-00543
Ultratec raised objective evidence of nonobviousness at the end
of its POR. °8 Referring to the evidence as "strong" and "directly
attributable to the claimed invention," it directed PTAB to two
supporting expert declarations describing substantial industry praise,
long-felt but unresolved need, commercial success of the products and
services embodying the invention, and the failure of others. 10 9 A third
supporting expert declaration "explain[ed], on a feature by feature
basis, the nexus between those secondary considerations and the
claimed design.""l 0 No further analysis or argument was made.
101 Id. at 57.
102 Permobil, Inc. v. Pride Mobility Products Corp., No. IPR2013-00407, Paper 26,
at 14 (P.T.A.B. May 20, 2014).
103 Id. at 15.
104 Permobil, Inc. v. Pride Mobility Products Corp., No. IPR2013-00407, Paper 53
(P.T.A.B. Dec. 31, 2014).
105 Id. at 21.
106 Id.
107 Id. at 22.
10 Captioncall, LLC v. Ultratec, Inc., No. IPR2013-00543, Paper 20, at 55
(P.T.A.B. May 12, 2014) (stating Ultratec did not submit a POPR).
109 Id. at 56.
11 Id. at 56-57.
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In its Reply, Petitioner attacked the evidence, but did not attack
Patent Owner's tactic of effectively "incorporating by reference" the
expert declarations."' According to Petitioner, there was "no
evidence that skilled workers, with knowledge of the prior art, tried to
solve any of the recounted problems and failed." ' 1 2 The praise was
not from those of skill in the art, nothing supported the assertions of
failure by others or copying, and none of the evidence showed
sufficient nexus to the claimed invention."
13
PTAB held all the instituted claims unpatentable.1 4  In
discussing the objective evidence, PTAB faulted Patent Owner for
only providing a list of secondary considerations evidence, without
substantive argument or explanation." 5  "This does not provide
sufficient analysis for us to determine whether Patent Owner has
provided adequate evidence of secondary considerations and a nexus
between any such evidence and the merits of the claimed
invention. ' ' 16 PTAB also found Patent Owner's experts' declarations
conclusory and unsupported.1 1 7  PTAB found that Petitioner's
showing of obviousness was not outweighed by Patent Owner's
asserted objective evidence.
e. Ariosa Diagnostics v. Verinata Health, Inc.,
No. IPR2013-00276
Verinata cited to Petitioner's past press releases and website
announcements about Petitioner's (allegedly directly infringing)
product as objective evidence of praise in the industry showing
nonobviousness. 
1 8
Petitioner's Reply noted that Verinata provided only evidence of
praise for the Ariosa product, and no evidence that the Ariosa
product falls within the claims. 1
19
ill Captioncall, LLC v. Ultratec, Inc., No. IPR2013-00543, Paper 33, at 13-15
(P.T.A.B. July 7, 2014).
112 Id. at 14.
113 d. at 14-15.
114 Captioncall, LLC v. Ultratec, Inc., No. IPR2013-00543, Paper 66 (P.T.A.B.
March 3, 2015).115 Id. at 26.
116 Id.
117 Id. at 27-28.
118 Ariosa Diagnostics v. Verinata Health, Inc., No. IPR2013-00276, Paper 20, at
56-57 (P.T.A.B. Jan. 16, 2014) (noting the concurrent patent infringement litigation);
Verinata Health, Inc. v. Ariosa Diagnostics, Inc., No. 3:12-cv-05501-SI, 2014 WL
7205108 (N.D. Cal. Dec. 17, 2014).
119 Ariosa Diagnostics v. Verinata Health, Inc., No. IPR2013-00276, Paper 26, at
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PTAB's Final Written Decision held that Petitioner did not show
that the challenged claims were unpatentable, but it was based on
Patent Owner's substantive patentability arguments, not the objective
evidence of nonobviousness.
120
4. No PGR Decisions on Objective Evidence Yet
As of Aug. 25, 2015, 13 post-grant review (PGR) petitions have
been filed; three have been instituted (PGR2015-00003, PGR2015-
00005, and PGR2015-00009). 12 ' Two were settled before a decision on
institution. In PGR2015-0003 and -0005, PTAB authorized Patent
Owner to file a motion requesting additional discovery on "certain
secondary indicia of non-obviousness," which it did.122 PTAB has not
yet issued a decision on the motion (as of Aug. 25, 2015). In
PGR2015-00009, Patent Owner waived the POPR.'
12 3
II. AN ISSUE FOR PATENT OWNERS, WHETHER FOR
INSTITUTION OR AT TRIAL, HAS BEEN WHETHER THE
OBJECTIVE EVIDENCE, EVEN IF IMPRESSIVE, IS LINKED
TO THE MERITS OF THE CLAIMED INVENTION
As can be seen from the above description of several cases,
Patent Owners are not having much success with objective evidence
persuading PTAB to either deny a petition or uphold the instituted
claims. So far, no PTAB final written decision has articulated
objective evidence of nonobviousness as its basis for finding in favor
of the Patent Owner. One institution denial has, 24 which will be
discussed in detail in Section III. An additional partial Patent Owner
success will be discussed in Section IV.1
25
12-13 (P.T.A.B. April 3, 2014).
120 Ariosa Diagnostics v. Verinata Health, Inc., No. IPR2013-00276, Paper 43
(P.T.A.B. Oct. 23, 2014).
121 Larose Industries, LLC V. Choon's Design Inc., No. PGR2014-00008, filed
Aug. 5, 2014; Accord Healthcare, Inc. v. Helsinn Healthcare S.A. and Roche Palo
Alto LLC, No. PGR2014-00010, filed Sept. 2, 2014 (showing one of the co-authors
represented Helsinn Healthcare); American Simmental Assn. v. Leachman Cattle of
Colorado, LLC, No. PGR2015-00003, filed Nov. 21, 2014; American Simmental Assn.
v. Leachman Cattle of Colorado, LLC, No. PGR2015-00005, filed Jan. 30, 2015.
122 American Simmental Assn. v. Leachman Cattle of Colorado, LLC, No.
PGR2015-00003, Paper 28 (P.T.A.B. Aug. 12, 2015).
123 See Netsirv v. Boxbee, Inc., No. PGR2015-00009, Paper 8 (P.T.A.B. May 6,
2015).
124 See Omron Oilfield & Marine, Inc. v. MD/TOTCO, A Division Of Varco, L.P.,
No. IPR2013-00265 (P.T.A.B. Dec. 12,1995).
125 Lupin Ltd. v. Vertex Pharms. Inc., No. IPR2015-00405, Paper 13 (P.T.A.B. July
9, 2015) (showing IPR instituted, but on fewer than all challenged claims).
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If objective evidence of nonobviousness is "the most probative
and cogent evidence of nonobviousness" and a "powerful tool[] for
courts faced with the difficult task of avoiding subconscious reliance
on hindsight,' 26 why aren't Patent Owners winning with objective
evidence? Perhaps, in cases where claims have survived a challenge,
PTAB has made that decision based on no prima facie case of
obviousness. In that situation, PTAB may well feel that objective
evidence of obviousness does not need to be articulated as a basis for
holding in favor of the Patent Owner.
So far, when PTAB does mention objective evidence, it tends to
show that PTAB is underwhelmed by the objective evidence of
nonobviousness presented, particularly focusing on a lack of nexus
shown between the objective evidence and the merits of the claimed
invention. For example, in Toyota Motor Corp. v. Leroy G.
Hagenbuch, No. IPR2013-00638, PTAB found the objective evidence
arguments relating to commercial success significantly lacking:
Patent Owner simply cites to the sales price of
Toyota's subscription service as commercial success.
... That does not establish "commercial success" as
objective evidence of nonobviousness. Patent Owner
does not provide information regarding sales volume
or market share information as compared to providers
of competing products. ... Furthermore, Patent Owner
has not even attempted to show a nexus between any
sales and the merits of the claimed invention. Although
Patent Owner references several claim limitations,
there is no explanation as to how these limitations are
related to the alleged commercial success of the
claimed invention other than simply alleging that the
limitations are present[.]
127
In Zodiac Pool Systems, Inc. v. Aqua Products, Inc., No.
IPR2013-00159, the same complaint was made about tying the
limitations to the asserted long-felt but unmet need:
Patent Owner fails to demonstrate that the recitations
of the challenged claims solve the other problems
126 Mintz v. Dietz & Watson, Inc., 679 F.3d 1372, 1378 (Fed. Cir. 2012); see also
Broadcom Corp. v. Emulex Corp., 732 F.3d 1325 (Fed. Cir. 2013).
127 Toyota Motor Corp. v. Leroy G. Hagenbuch, No. IPR2013-00638, Paper 42, at
23 (P.T.A.B. Jan. 30, 2015).
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which Patent Owner contends are the subject of long-
felt need.... Consequently, to the extent that Patent
Owner may have shown that these problems represent
a long-felt need, Patent Owner fails to show a nexus
between that need and limitations recited in the
challenged claims of the '183 Patent.
128
Pharmatech Solutions, Inc. v. Lifescan Scotland, Ltd., No.
IPR2013-00247, provides an example with respect to copying:
Because LifeScan has not shown nexus convincingly, the
objective evidence does not persuade us that the apparent
copying of its test strips can be traced to the claimed
subject matter.129
Failure to tie the objective evidence to the merits of the claimed
invention seems to be a major reason why Patent Owners have been
disappointed by reliance on such evidence.
130
PTAB is consistently citing to Federal Circuit cases for the
standard of nexus that is required for objective evidence of
nonobviousness to be considered persuasive. For example:
[A]s the Federal Circuit held in Ormco Corp. v. Align
Tech., Inc., 463 F.3d 1299, 1311-12 (Fed. Cir. 2006),
"[e]vidence of commercial success, or other secondary
considerations, is only significant if there is a nexus
between the claimed invention and the commercial
success." Id. .... In order to establish a proper nexus, the
patent owner must offer "proof that the sales were a
direct result of the unique characteristics of the
claimed invention -- as opposed to other economic and
commercial factors unrelated to the quality of the
patented subject matter." In re Huang, 100 F.3d 135,
140 (Fed. Cir. 1996) (citation omitted) (concluding that
the patentee failed to establish nexus). In In re DBC,
128 Zodiac Pool Systems, Inc. v. Aqua Products, Inc., No. IPR2013-00159, Paper
71, at 36 (P.T.A.B. Aug. 22, 2014)
129 Pharmatech Solutions, Inc. v. Lifescan Scotland, Ltd., No. IPR2013-00247,
Paper 27, at 22 (P.T.A.B. Aug. 6, 2014).
See Cardiocom, LLC v. Robert Bosch Healthcare Systems, Inc., No. IPR2013-
00468, Paper 72 (P.T.A.B. Jan. 27, 2015) (explaining PTAB found nexus lacking
between each of evidence of commercial success, long-felt need, industry praise,
teaching away by others, and copying).
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545 F.3d 1373 (Fed. Cir. 2008), the Federal Circuit
observed that "[Patentee] has done little more than
submit evidence of sales," concluding that "[hiowever
substantial those sales, that evidence does not reveal in
any way that the driving force behind those sales was
the claimed [invention]." Id. at 1384 (Emphasis
added).
Where, as here, the patent is said to cover a feature or
component of a product, the patent owner has the
additional burden of showing that the commercial
success derives from the feature. Tokai Corp. v. Easton
Enters., 632 F.3d 1358, 1369 (Fed. Cir. 2011). Further,
especially where the feature is found in the product of
another, there must be proof that it falls within the
claims. E.g., Demaco Corp. v. F. Von Langsdorff
Licensing Ltd., 851 F.2d 1387, 1392 (infringer's counsel
stated at trial that the patent had been copied); Hughes
Tool Co. v. Dresser Industries, Inc., 816 F.2d 1549,
1552 (Fed. Cir. 1987) (patented 0-ring seal copied by
defendant).13 '
These are familiar standards to patent practitioners.
A challenge for Patent Owners facing IPRs and PGRs to
adequately address objective evidence arguments is the page limit on
POPRs and PORs. In addition, the current restriction on no
declaration testimony specifically generated for the IPR with the
POPR is a challenge for Patent Owners. 132 Furthermore, PTAB has
131 See Microsoft Corp. v. Proxyconn, Inc., No. IPR2012-00026, Paper 32, at 4-5
(P.T.A.B. March 8, 2013) (Denying Proxyconn's motion for additional discovery to
obtain evidence of "secondary considerations of non-obviousness." In authorizing the
motion, PTAB had expressly ordered Patent Owner to address nexus: "Patent
Owner's motion will specifically identify the information sought and address the
relevance of that information, including the nexus between the information sought
and the allegation of commercial success (Emphasis added)."(Emphasis in original).
See also, MasterImage 3D Asia, LLC v. RealD, Inc., No. IPR2015-00035, Paper 28, at
3 (P.T.A.B. June 23, 2015)(denying Patent Owner's request for authorization to file a
motion for additional discovery: "allegations that Petitioner may have discussed
Patent Owner's product does not, in and of themselves, reflect more than a "mere
possibility" or "mere allegation that something useful [to the proceeding] will be
found" on the issue of copying .... With respect to commercial success, Patent
Owner has not presented a threshold showing of nexus with respect to the claims").
132 37 C.F.R. § 42.107(3) (2014); 37 C.F.R. § 42.207(3) (2014) (explaining on Aug.
20, 2015, the United States Patent & Trademark Office (USPTO) released proposed
rules that may change the use of new evidence in POPRs).
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made it clear that assertions made only in declarations and not
developed in the attorney argument will not be considered.'33
This means that the Patent Owner possibly faces a difficult
decision as to how many pages to devote to addressing the asserted
unpatentability grounds and how many pages to devote to objective
evidence of nonobviousness and the nexus between that evidence and
the merits of the claimed invention.
III. MAKING THE NECESSARY LINK (NEXUS) BETWEEN
OBJECTIVE EVIDENCE OF NONOBVIOUSNESS AND THE
CLAIMED INVENTION
PTAB's instructions are clear: "To show how commercial success
supports nonobviousness, Patent Owner must prove that the sales
were a direct result of the unique characteristics of the invention, and
not a result of economic and commercial factors unrelated to the
quality of the patented subject matter.' ' 134 This "nexus" between the
evidence and the claimed invention "is a legally and factually
sufficient connection.''
135
Looking to the Federal Circuit case law, a few more guiding
principles can be found:
If the feature that created the commercial success was
known in the prior art, the success is not pertinent to the
issue of obviousness.'
36
Information solely on numbers of units sold is insufficient
to establish commercial success.
137
[S]elf-referential commendation fall[s] well short of
demonstrating true industry praise.'
38
133 Conopco, Inc. v. Procter & Gamble Co., No. IPR2013-00505, Paper 69, at 27
(P.T.A.B. Feb. 10, 2015) ("We decline to consider, moreover, information presented
in a supporting declaration, but not discussed sufficiently in Patent Owner's
Response."); 37 C.F.R. § 42.6(a)(3) (2014).
134 Toyota Motor Corp. v. Leroy G. Hagenbuch, No. IPR2013-00638, Paper 42, at
24(P.T.A.B. Jan. 30, 2015).
5 Demaco Corp. v. F. Von Langsdorff Licensing Ltd., 851 F.2d 1387, 1392 (Fed.
Cir. 1988).
136 Galderma Labs., L.P. v. Tolmar, Inc., 737 F.3d 731, 740 (Fed. Cir. 2013).
137 In re Baxter Travenol Labs., 952 F.2d 388, 392 (Fed. Cir. 1991).
138 Bayer Healthcare Pharm., Inc. v. Watson Pharm., Inc., 713 F.3d 1369, 1377
(Fed. Cir. 2013).
2015]
128 BUFFALO INTELLECTUAL PROPERTY LA WJOURNAL [Vol XI
Omron Qilfield & Marine, Inc. v. MDiTOTCO, A Division Of
Varco, L.P., No. IPR2013-00265, provides an example of a case where
the Patent Owner raised objective evidence of nonobviousness
presented during a reexamination, and, after finding a prima facie
case of obviousness was made out by Petitioner, PTAB analyzed the
objective evidence, balanced it against the evidence of obviousness,
and found the objective evidence of nonobviousness persuasive.
Petitioner noted that Patent Owner raised objective evidence of
nonobviousness in the reexamination of the patent.139 According to
Petitioner, the examiner "never retreated from his position that the
claims are prima facie obvious ... [but] found that the Patent Owner's
showing of secondary considerations overcame the obviousness
rejection. 1 40 Petitioner argued that since it was raising prior art not
considered during prosecution or reexamination, the Patent Owner's
objective evidence of nonobviouness "will be unable to overcome the
strong showing of obviousness set forth in this Petition.' 14'
Patent Owner filed a POPR, arguing that the petition should be
denied because the USPTO "already determined the overpowering
evidence of secondary considerations of non-obviousness overcomes
even a prima facie case' 42 and attached the expert declarations from
prosecution containing objective evidence of nonobviousness and
linking that evidence to the claimed invention.1 43 Patent Owner then
compared the prior art disclosures examined in the initial prosecution,
two reexaminations, and the Petition, and argued that the Petitioner's
art and arguments "for obviousness in its petition are identical to the
disclosures already considered by the PTO in analyzing
obviousness.'"144
PTAB denied institution on all challenged claims. 45 PTAB
found Petitioner had established a prima facie case of obviousness.
PTAB then turned to the objective evidence of nonobviousness,
reviewed the examiner's findings with respect to it, and agreed that
"patent owner's evidence of secondary considerations is
139 Omron Oilfield & Marine, Inc. v. MD/TOTCO, A Division of Varco, L.P., No.
IPR2013-00265, Paper 1, at 9-10 (P.T.A.B. May 3, 2013).
140 Id. at 9.
141 Id. at 10.
142 Omron Oilfield & Marine, Inc. v. MD/TOTCO, A Division of Varco, L.P., No.
IPR2013-00265, Paper 10, at 42 (P.T.A.B. Aug. 6, 2013).
143 Id. at 9 n.12.
144 Id. at 44.145 Omron Oilfield & Marine, Inc. v. MD/TOTCO, A Division of Varco, L.P., No.
IPR2013-00265, Paper 11 (P.T.A.B. Oct. 31, 2013).
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persuasive., 146
The objective evidence included commercial success, long-felt
but unmet need, failure of others, and unexpected results.
Patent Owner's evidence of commercial success was a brochure
featuring the invention and trial testimony that the product was
successful due to the patented features. "A prima facie case of nexus
is established when the patentee shows both that there is commercial
success, and that the product that is commercially successful is the
invention disclosed and claimed in the patent., 147 PTAB found that
"[b]ased on the record cited above, we determine that Patent Owner
has presented sufficient evidence to establish a prima facie case of
nexus."'148  Patent Owner presented evidence that the claimed
invention was successful, including sales growth and evidence of the
growth of a product later judged infringing. 149
Petitioner did not submit rebuttal evidence, and PTAB
concluded that the Patent Owner presented sufficient evidence to
establish that the claimed invention was "a significant commercial
success." 150
Patent Owner did not provide sufficient evidence supporting
long-felt but unmet need or unexpected results. The evidence of
significant commercial success, however, overcame the prima facie
case of obviousness.
151
Petitioner requested rehearing, arguing that PTAB abused its
discretion by denying trial "based solely on evidence of purported
commercial success that Patent Owner developed through direct
testimony in a civil litigation that did not involve Petitioner in any
way.' '152 Petitioner attacked the objective evidence and argued that
PTAB "misapprehended the strength of petitioner's prior art.' 5 3
PTAB denied Petitioner's request for rehearing.' 54 First, it cited
35 U.S.C. § 325(d), noting that the references relied upon in the
Petition were "not substantially different from the references before
the Office in a prior ex parte reexamination in which the patentability
146 Id. at 13.
147 Id. at 14.
148 Id. at 15.
149 Id.
150 Id. at 16.
151 Id.
152 Omron Oilfield & Marine, Inc. v. MD/TOTCO, A Division of Varco, L.P., No.
IPR2013-00265, Paper 12, at 1 (P.T.A.B. Dec. 2, 2013).
153 Id. at 10.
154 Omron Oilfield & Marine, Inc. v. MD/TOTCO, A Division of Varco, L.P., No.
IPR2013-00265, Paper 14 (P.T.A.B. Feb. 13, 2014).
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of the challenged claims was confirmed" based on the evidence of
commercial success. 155  "In other words, we concluded that the
Petition presented the same, or substantially the same, prior art and
arguments to the Office as those overcome in the reexamination.
156
Petitioner knew of the evidence presented in the reexamination, and
could have addressed it in the Petition, but did not.157 Addressing the
objective evidence in the rehearing request was too late: "we are not
persuaded by Petitioner's new arguments regarding the merits or
admissibility of the evidence of secondary considerations." '1 58
Sufficient nexus to a request for additional discovery of objective
evidence was shown in John's Lone Star Distribution, Inc. v.
Thermolife Int'l, LLC, No. IPR2014-01201.159  Patent Owner
requested additional discovery of documents relating to evidence of
commercial success. PTAB partially granted the request, finding
sufficient nexus between the request for certain sales information and
the claim limitations:
Patent Owner points us to evidence indicating that
potentially relevant products have enjoyed at least some
commercial success, after being advertised as containing
components recited in challenged claims, such as a nitrate
and at least one amino acid, and as increasing vasodilation
and nutrient absorption .... In addition, Patent Owner is
not required to provide "comparative sales information" or
its own sales data in a motion for additional discovery,
even if such information and evidence would be
appropriately cited in a Patent Owner Response. Here,
prior to filing its Response, Patent Owner seeks discovery
on the issue of commercial sales of three products by a
competitor, most likely to bolster evidence Patent Owner
may already have in its possession relating to the issue of
commercial success generally. In view of contentions of
both parties, as well as evidence before us, we are
persuaded that Patent Owner has set forth a threshold
amount of evidence sufficient to deem that the discovery of
155 Id. at 3.
156 Id.
157 Id.
158 Id. at 4.
159 John's Lone Star Distribution, Inc. v. Thermolife Int'l, LLC, No. IPR2014-
01201, Paper 30 (P.T.A.B. May 13, 2015), in addition to meeting the Garmin factors
for additional discovery requests (see Garmin Int'l, Inc. v. Cuozzo Speed
Technologies, LLC, No. IPR2012-00001, Paper 26, at 6-7 (P.T.A.B. March 5, 2013)).
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certain requested documents is necessary in the interest of
justice. Specifically, we authorize additional discovery from
Petitioner in relation Patent Owner's Request (2)[.] 160
IV. SHOWING THAT THE OBJECTIVE EVIDENCE OF
NONOBVIOUSNESS IS COMMENSURATE IN SCOPE WITH
THE BREADTH OF THE CLAIMED INVENTION
As in all other obviousness determinations, whether they are in
litigation or in prosecution, the objective evidence of nonobviousness
has to be evaluated in the context of the scope of the claimed
invention. 161 In Zodiac Pool Systems, Inc. v. Aqua Products, Inc.,
IPR2013-00159, Patent Owner argued that the long-felt but unmet
need was for an efficient, automated cleaning device. In particular,
"[c]ontrolling the movement of the cleaner was critical to avoiding the
twisting of the electric cable which would seriously impede the
cleaner's operation."' 62 Petitioner attacked that argument by pointing
out that the claim did not require or describe controlled movement or
solve the other problems making up the long-felt need ("susceptibility
of parts to wear and breakdown and elimination of power supply
cables"). 163 PTAB rejected Patent Owner's objective evidence for not
demonstrating "adequately that the challenged claims represent a
solution to the alleged long-felt need."' 64
An IPR was instituted in Lupin Ltd. v. Vertex Pharms. Inc.,
IPR2015-00405, 65 but it was instituted on fewer than all challenged
claims and fewer than all asserted grounds based on the objective
evidence of nonobviousness the Patent Owner was able to point to in
its POPR. In particular, Patent Owner argued that evidence of
unexpected results, long-felt need, copying of others, failure of others,
and commercial success rebutted any prima facie case of obviousness.
The evidence came from articles, clinical studies, deposition transcript
from another IPR of patent owner's expert, and labels. Petitioner
160 Id. at 4-5.
161 Zodiac Pool Sys., Inc. v. Aqua Prods., Inc., No. IPR2013-00159, Paper 71, at 34
(P.T.A.B. Aug. 22, 2014), citing In re Kao, 639 F.3d 1057, 1068 (Fed. Cir. 2011) (citing
In re Tiffin, 448 F.2d 791, 792 (CCPA 1971)); In re Hiniker Co., 150 F.3d 1362, 1369
(Fed. Cir. 1998).
162 Zodiac Pool Sys., Inc. v. Aqua Prods., Inc., No. IPR2013-00159, Paper 28, at 17
(P.T.A.B. Nov. 25, 2013).
163 Zodiac Pool Sys., Inc. v. Aqua Prods., Inc., No. IPR2013-00159, Paper 44, at 9-
11 (P.T.A.B. Mar. 10, 2014).
Zodiac Pool Sys., Inc. v. Aqua Prods., Inc., No. IPR2013-00159, Paper 71, at 36
(P.T.A.B. Aug. 22, 2014).
165 Lupin Ltd. v. Vertex Pharms. Inc., No. IPR2015-00405, Paper 13 (P.T.A.B. July
9, 2015).
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knew of this evidence and addressed it briefly in its petition.
PTAB found the objective evidence of nonobviousness
persuasive with respect to claims directed to specific compounds and
compositions.' 66 However, the evidence was not "commensurate in
scope" with broader claims, and the IPR petition was granted with
respect to those claims.167
Federal Circuit precedent provides guidance for showing the
objective evidence of nonobviousness is commensurate in scope with
the claims. For example, the case law holds that evidence of
commercial success is relevant if the item sold was within the scope of
the claims, even if not all possible embodiments within the claims
were successfully commercialized.168
V. PROSECUTION DECLARATIONS TO SUPPORT
NONOBVIOUSNESS POSITIONS MAY BE EFFECTIVE TO
OBTAIN DENIAL OF IPR PETITION
A. In The POPR, Currently Patent Owner Cannot Rely On
Evidence "Taken Specifically for the Purpose of the Inter Partes
Review" 69 But, to Defeat Institution, the Patent Owner Should
Be Able to Rely on Declarations Setting Forth Objective
Evidence of Nonobviousness and Originating from the
Prosecution1 70
Depending on the particular circumstances and objectives of
each patent application, the Patent Owner may consider developing
and submitting declarations during the original prosecution or
prosecution of related cases providing objective evidence of
nonobviousness. Such declarations may be useful later in a POPR in
an effort to persuade PTAB to deny institution. A denial of a petition
166 Id. at 22-23.
167 Id. at 23.
168 See In re Glatt Air Techniques, 630 F.3d 1026, 1030 (Fed. Cir. 2011); Applied
Materials, Inc. v. Adv. Semiconductor Materials Am., Inc., 98 F.3d 1563, 1570 (Fed.
Cir. 1996); In re Hollingsworth, 253 F.2d 238, 240-41 (C.C.P.A. 1958).
169 See 37 C.F.R. § 42.107; see also Anova Food, LLC v. Sandau, No. IPR2013-
00114, Paper 11, at 3 (P.T.A.B. June 25, 2013) (noting "The Board responded that 37
C.F. R § 42.107(c) applies only to "new" testimony that was taken specifically for the
purpose of the inter partes review proceeding at issue, as supported by the discussion
and the comments that accompanied the rule. For example, a party submitting the
prosecution history for the challenged patent may include a copy of the declarations
contained therein").
170 On Aug. 20, 2015, the United States Patent & Trademark Office (USPTO)
released proposed rules that may change the use of new evidence in POPRs. See 80
Fed. Reg. 50,720 (Aug. 20, 2015).
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in full is a "win" for the Patent Owner because all of the challenged
claims remain intact, and the institution decision is not appealable.' 7 '
B. Requires Careful Thought and Planning
Any declaration, of course, should be considered and planned
carefully. PTAB has found that defective declarations relied on for
patentability during prosecution can form an independent basis for
instituting an IPR. 7 2 Moreover, the declaration testimony proffered
during prosecution to establish objective evidence of nonobviousness
may be subject to intense scrutiny in any eventual litigation. In
particular, the doctrine of inequitable conduct is alive and well post-
Therasense.173 Although inequitable conduct cannot be raised during
an IPR or PGR, there is apparently no estoppel precluding a losing
IPR or PGR petitioner from raising inequitable conduct in a
subsequent litigation, based perhaps on the prosecution declaration
providing the objective evidence of nonobviousness.
VI. CONCLUSION
Objective evidence of nonobviousness may be raised by the
Patent Owner in its POPR or POR to rebut a prima facie case of
obviousness. In IPRs so far, Patent Owners have mostly experienced
disappointment before PTAB with arguments based on objective
evidence of nonobviousness. Based on examples of objective
evidence arguments made in such IPRs so far, it appears that Patent
Owners are not sufficiently linking the objective evidence of
nonobviousness to the merits of the claimed invention. More
attention to this linking may lead to more Patent Owner success with
these arguments, particularly since "objective evidence" may be the
strongest evidence of nonobviousness. 174  Declarations supporting
nonobviousness positions, prepared prior to and for a reason other
than the IPR, may provide a useful tool for Patent Owners to then
leverage in POPRs of future IPRs. If the USPTO's proposed rule
"' 35 U.S.C. §314(d) and 35 U.S.C. §324(e).
172 K-40 Electronics, LLC v. Escort, Inc., No. IPR2013-00203, Paper 6 (P.T.A.B.
Aug. 29, 2013).
13 See, e.g., Aventis Pharma S.A. v. Hospira, Inc., 675 F.3d 1324 (Fed. Cir. 2012);
Apotex Inc. v. Cephalon, Inc., No. 2:06-CV-2768, 2011 WL 6090696, at *1 (E.D. Pa.
Nov. 7, 2011) aff'd without opinion, 500 F.App'x 959 (Fed. Cir. 2013); Intellect
Wireless, Inc. v. HTC Corp., 732 F.3d 1339 (Fed. Cir. 2013); Ohio Willow Wood Co.
v. Alps South, LLC, 735 F.3d 1333 (Fed. Cir. 2013); Apotex, Inc. v. UCB, Inc., 763
F.3d 1354 (Fed. Cir. 2014); American Calcar, Inc. v. American Honda Motor Co., 768
F.3d 1185 (Fed. Cir. 2014).
174 See supra section lB.
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amendment allowing declaration evidence to be prepared to support a
POPR becomes a final rule, Patent Owners may have more resources
at their disposal to support arguments of objective evidence.
